Evidence map›Paper›PMID 35331191›Full record

Trial reportBMC psychiatry2022

Comparing a mindfulness- and CBT-based guided self-help Internet- and mobile-based intervention against a waiting list control condition as treatment for adults with frequent cannabis use: a randomized controlled trial of CANreduce 3.0.

Michelle Dey, Andreas Wenger, Christian Baumgartner, Ute Herrmann, Mareike Augsburger, Severin Haug, Doris Malischnig, Michael P Schaub

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Michelle DeySwiss Research Institute for Public Health and Addiction at the University of Zurich, Konradstrasse 32, 8005, Zurich, Switzerland. michelle.dey@isgf.uzh.ch.ORCID 0000-0002-4300-1877
Andreas WengerSwiss Research Institute for Public Health and Addiction at the University of Zurich, Konradstrasse 32, 8005, Zurich, Switzerland.
Christian BaumgartnerSwiss Research Institute for Public Health and Addiction at the University of Zurich, Konradstrasse 32, 8005, Zurich, Switzerland.
Ute HerrmannCantonal Hospital Winterthur, Institute for Anesthesiology, Pain Center, Brauerstrasse 15, 8401, Winterthur, Switzerland.
Mareike AugsburgerSwiss Research Institute for Public Health and Addiction at the University of Zurich, Konradstrasse 32, 8005, Zurich, Switzerland.
Severin HaugSwiss Research Institute for Public Health and Addiction at the University of Zurich, Konradstrasse 32, 8005, Zurich, Switzerland.
Doris MalischnigOffice of Addiction and Drug Policy of Vienna, Institute for Addiction Prevention, Modecenterstrasse 14, 1030, Vienna, Austria.
Michael P SchaubSwiss Research Institute for Public Health and Addiction at the University of Zurich, Konradstrasse 32, 8005, Zurich, Switzerland.
University of Zurich · CHKantonsspital Winterthur · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThough Internet- and mobile-based interventions (IMIs) and mindfulness-based interventions (generally delivered in-situ) appear effective for people with substance use disorders, IMIs incorporating mindfulness are largely missing, including those targeting frequent cannabis use.

methodsThis paper details the protocol for a three-arm randomized controlled trial comparing a mindfulness-based self-help IMI (arm 1) and cognitive-behavioral therapy (CBT)-based self-help IMI (arm 2) versus being on a waiting list (arm 3) in their effectiveness reducing cannabis use in frequent cannabis users. Predictors of retention, adherence and treatment outcomes will be identified and similarities between the two active intervention arms explored. Both active interventions last six weeks and consist of eight modules designed to reduce cannabis use and common mental health symptoms. With a targeted sample size of n = 210 per treatment arm, data will be collected at baseline immediately before program use is initiated; at six weeks, immediately after program completion; and at three and six months post baseline assessment to assess the retention of any gains achieved during treatment. The primary outcome will be number of days of cannabis use over the preceding 30 days. Secondary outcomes will include further measures of cannabis use and use of other substances, changes in mental health symptoms and mindfulness, client satisfaction, intervention retention and adherence, and adverse effects. Data analysis will follow ITT principles and primarily employ (generalized) linear mixed models. DISCUSSION: This RCT will provide important insights into the effectiveness of an IMI integrating mindfulness to reduce cannabis use in frequent cannabis users.

trial registrationInternational Standard Randomized Controlled Trial Number Registry: ISRCTN14971662 ; date of registration: 09/09/2021.

Indexed as

CannabisCognitive Behavioral TherapyMindfulnessAdultHumansInternetTreatment OutcomeWaiting ListsCannabisCognitive-behavioral therapyInternet-based interventionMindfulnessRandomized controlled trialSelf-help

Identifiers

PMID35331191
PMCPMC8943921
OpenAlexW4220762447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.